Genmab Stock (GMAB) Soars Over 30% on Strong Phase 3 Results for the Company’s Head and Neck Cancer Treatment
Genmab stock saw an over 30% rally on Wednesday following a clinical trial update for its head and neck cancer drug.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Orbis Investment Management William B. Gray | 10,567,391 | $376,991,674 | -8% | 1.25% |
| 2. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 6,069,276 | $216,521,421 | +22% | 0.09% |
| 3. | Two Sigma Advisors John Overdeck And David Siegel | 5,252,719 | $187,390,750 | 0.13% | |
| 4. | Deep Track Capital David Kroin | 4,182,689 | $149,217,430 | -26% | 2.43% |
| 5. | 2,760,000 | $98,463,000 | -8% | 1.6% |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,057,192 | $216,090,316 | 0% | |
| 2. | 3,900,744 | $139,159,050 | 0.02% | |
| 3. | 3,225,639 | $115,074,671 | 0.07% | |
| 4. | 1,497,563 | $82,545,673 | 0.02% | |
| 5. | 1,715,194 | $61,189,638 | 0% |